Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Current Investments (2021 - 2025)

ARS Pharmaceuticals' Cash & Current Investments history spans 5 years, with the latest figure at $245.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 21.98% year-over-year to $245.0 million; the TTM value through Dec 2025 reached $245.0 million, down 21.98%, while the annual FY2025 figure was $245.0 million, 21.98% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $245.0 million at ARS Pharmaceuticals, down from $288.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $374.2 million in Q1 2021 and bottomed at $60.1 million in Q4 2021.
  • The 5-year median for Cash & Current Investments is $255.9 million (2022), against an average of $257.2 million.
  • The largest YoY upside for Cash & Current Investments was 356.82% in 2022 against a maximum downside of 32.16% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $60.1 million in 2021, then skyrocketed by 356.82% to $274.4 million in 2022, then dropped by 16.77% to $228.4 million in 2023, then soared by 37.51% to $314.0 million in 2024, then decreased by 21.98% to $245.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Cash & Current Investments are $245.0 million (Q4 2025), $288.2 million (Q3 2025), and $240.1 million (Q2 2025).